Top Markets
#1 Black Phoenix Black Phoenix +354.85%
#2 Glidr Glidr +84.34%
#3 Gold Park Gold Park +55.17%
#4 Akedo Akedo +51.00%
#5 Acurast Acurast +31.40%
#6 BasedHype BasedHype +23.42%
#7 Cryptopia Cryptopia +21.54%
#8 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +21.41%
#9 Avantis Avantis +19.21%
#10 Quantum Resistant Ledger Quantum Resistant Ledger +15.52%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
Histogen Inc. Histogen Inc.

Histogen Inc.

HSTO
Rank in Stocks #40868
Histogen Inc. operates as a clinical-stage biotechnology company, focusing on... Histogen Inc. operates as a clinical-stage biotechnology company, focusing on the development of novel, stem cell-free biologic products derived from its proprietary hypoxia-generated growth factor technology platform. Among its offerings is HST-003, a human extracellular matrix, currently undergoing Phase 1/2 clinical trials to mend articular cartilage defects in the knee. Additionally, the company is advancing HST-004, a cell-conditioned media solution designed for spinal disc repair, and Emricasan, an orally active pan-caspase inhibitor targeting COVID-19 treatment. In its preclinical pipeline, Histogen is developing CTS-2090 and CTS-2096. These are selective caspase-1 inhibitors formulated to suppress inflammasome activation and intervene in a range of inflammation-mediated conditions. Founded in 2007, Histogen Inc. maintains its headquarters in San Diego, California.
Share Price
$0.02765
Last synced: 2024-12-23
Market Cap
$69.04K
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Histogen Inc. (HSTO)

Category

Healthcare
P/B ratio for Histogen Inc. (HSTO)
P/B ratio as of August 2026 TTM: 0.00
According to Histogen Inc. latest financial reports and stock price the company's current price-to-book ratio (TTM) is 0.00. At the end of 2021 the company had a P/B ratio of 0.06.
P/B ratio history for Histogen Inc. from 2011 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
2026 (TTM) 0.00 -77.50%
2022 0.02 -69.01%
2021 0.06 -31.54%
2020 0.09 -168.39%
2019 -0.13 -166.48%
2018 0.19 -59.34%
2017 0.47 -13.89%
2016 0.55 -98.24%
2015 31.05 -52.41%
2014 65.25 265.13%
2013 17.87 0.00%
2012 0.00 0.00%
2011 0.00 0.00%
P/B ratio for similar companies or competitors
Company P/B Ratio P/B Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.2613 139,040.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.3483 140,973.33%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 3.634 80,655.56%
BE